P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trialsMarco Valgimigli, Roxana Mehran, Pascal Vranckx et al.|BMJ|2021Cited by 254
Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical TrialRoberto Galea, Marco Valgimigli, Federico De Marco et al.|Circulation|2021Cited by 138
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary InterventionsFelice Gragnano, Marco Valgimigli, Roxana Mehran et al.|Journal of the American College of Cardiology|2023Cited by 119
Impact of Left Ventricular Outflow Tract Calcification on Procedural Outcomes After Transcatheter Aortic Valve ReplacementTaishi Okuno, Thomas Pilgrim, Masahiko Asami et al.|JACC: Cardiovascular Interventions|2020Cited by 116
De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trialsMarco Valgimigli, Myeong‐Ki Hong, Sung‐Jin Hong et al.|The Lancet|2024Cited by 93